{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:50:50Z","timestamp":1781297450675,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and Objective:<\/jats:bold> Over the past few years, mirabegron has been increasingly used as a therapeutic option for neurogenic lower urinary tract dysfunction. Here, we carried out a meta-analysis to investigate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We used a range of databases to retrieve randomized controlled trials (RCTs) relating to mirabegron in patients with neurogenic lower urinary tract dysfunction: PubMed, Embase, and Cochrane Library; our strategy conformed to the PICOS (populations, interventions, comparators, outcomes, and study designs) strategy.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Our analyses involved four RCTs involving 245 patients. We found that mirabegron treatment resulted in a significant improvement in bladder compliance [mean difference (MD) = 19.53, 95% confidence interval (CI): 14.19 to 24.87, P &amp;lt; 0.00001], urinary incontinence episodes (MD = \u22120.78, 95% CI: \u22120.89 to \u22120.67, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001) and Incontinence Quality of Life (I-QOL) (MD = 8.02, 95% CI: 3.20 to 12.84, <jats:italic>P<\/jats:italic> = 0.001). Significant differences were detected in terms of Patient Perception of Bladder Condition (PPBC) (MD = \u22120.54, 95% CI: \u22121.46 to 0.39, <jats:italic>P<\/jats:italic> = 0.26) and urinary urgency episodes (MD = \u22120.72, 95% CI: \u22123.1 to 1.66, <jats:italic>P<\/jats:italic> = 0.55). With regard to safety, there were no significant differences between mirabegron and control groups in terms of the incidence of drug-related adverse events [odds ratio (OR): 0.83, 95% CI: 0.43 to 1.59, <jats:italic>P<\/jats:italic> = 0.57], arrhythmias (OR: 1.27, 95% CI: 0.37 to 4.38, <jats:italic>P<\/jats:italic> = 0.70), hypertension (OR: 0.70, 95% CI: 0.13 to 3.82, <jats:italic>P<\/jats:italic> = 0.68), or post-voiding residual volume (MD: 1.62, 95% CI: \u22129.00 to 12.24, <jats:italic>P<\/jats:italic> = 0.77).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Mirabegron is an efficacious and safe treatment for patients with neurogenic lower urinary tract dysfunction.<\/jats:p>","DOI":"10.3389\/fphar.2021.756582","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T06:16:30Z","timestamp":1637216190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Dongxu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengze","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","volume-title":"Randomised Controlled Trials","author":"Alejandro","year":"1998"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1590\/s1677-55382011000100003","article-title":"Constipation and LUTS - How Do They Affect Each Other?","volume":"37","author":"Averbeck","year":"2011","journal-title":"Int. Braz. J. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/nau.22629","article-title":"Comparison of the Effects of \u03b23 -adrenoceptor Agonism on Urinary Bladder Function in Conscious, Anesthetized, and Spinal Cord Injured Rats","volume":"34","author":"Beauval","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jsm.12885","article-title":"The Relationship between Metabolic Syndrome, its Components, and Erectile Dysfunction: a Systematic Review and a Meta-Analysis of Observational Studies","volume":"12","author":"Besiroglu","year":"2015","journal-title":"J. Sex. Med."},{"key":"B5","first-page":"121","article-title":"International Union of Pharmacology Nomenclature of Adrenoceptors","volume":"46","author":"Bylund","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in Overactive Bladder: A Review of Efficacy, Safety, and Tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"B7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and Adherence with Mirabegron Versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"O53","DOI":"10.1111\/luts.12215","article-title":"Therapeutic Efficacy of Low-Dose (25\u2009mg) Mirabegron Therapy for Patients with Mild to Moderate Overactive Bladder Symptoms Due to central Nervous System Diseases","volume":"11","author":"Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"B9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.24552","article-title":"Mirabegron for Treatment of Overactive Bladder Symptoms in Patients with Parkinson's Disease: A Double-Blind, Randomized Placebo-Controlled Trial (Parkinson's Disease Overactive Bladder Mirabegron, PaDoMi Study)","volume":"40","author":"Cho","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The Validation of the Patient Perception of Bladder Condition (PPBC): A Single-Item Global Measure for Patients with Overactive Bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-Analysis in Clinical Trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. T Rials"},{"key":"B12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-Analysis in Clinical Trials Revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"B13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","article-title":"Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology","volume":"69","author":"Groen","year":"2016","journal-title":"Eur. Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MOU.0000000000000290","article-title":"Neurourologic Dysfunction: Evaluation, Surveillance and Therapy","volume":"26","author":"Harris","year":"2016","journal-title":"Curr. Opin. Urol."},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-021-00455-2","article-title":"Mirabegron Improves Erectile Function in Men with Overactive Bladder and Erectile Dysfunction: A 12-week Pilot Study","volume":"32","author":"Karakus","year":"2021","journal-title":"Int. J. Impot Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1517\/17425255.2013.786700","article-title":"The Pharmacokinetic Evaluation of Mirabegron as an Overactive Bladder Therapy Option","volume":"9","author":"Kashyap","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-128","article-title":"Incidence and Prevalence of Multiple Sclerosis in Europe: A Systematic Review","volume":"13","author":"Kingwell","year":"2013","journal-title":"BMC Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vascn.2017.04.008","article-title":"Translational Science Approach for Assessment of Cardiovascular Effects and Proarrhythmogenic Potential of the Beta-3 Adrenergic Agonist Mirabegron","volume":"87","author":"Korstanje","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Detrusor Overactivity-Prospective, Randomized, Double-Blind, Placebo-Controlled Study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sc.2012.158","article-title":"The Global Map for Traumatic Spinal Cord Injury Epidemiology: Update 2011, Global Incidence Rate","volume":"52","author":"Lee","year":"2014","journal-title":"Spinal Cord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur. Urol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur. Urol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and Healthcare Utilization of Neurogenic Bladder Patients in a US Claims Database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/iju.12093","article-title":"Expression and Functional Role of \u03b23 -Adrenoceptors in the Human Ureter","volume":"20","author":"Matsumoto","year":"2013","journal-title":"Int. J. Urol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11934-020-01017-7","article-title":"Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia","volume":"22","author":"Mullen","year":"2021","journal-title":"Curr. Urol. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD004193","DOI":"10.1002\/14651858.CD004193.pub3","article-title":"Withdrawn: Anticholinergics for Urinary Symptoms in Multiple Sclerosis","volume":"6","author":"Nicholas","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0090-4295(98)00454-3","article-title":"Quality of Life of Women with Urinary Incontinence: Further Development of the Incontinence Quality of Life Instrument (I-QOL)","volume":"53","author":"Patrick","year":"1999","journal-title":"Urology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.rehab.2017.02.008","article-title":"What Do We Know about Neurogenic Bladder Prevalence and Management in Developing Countries and Emerging Regions of the World?","volume":"60","author":"Przydacz","year":"2017","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14740338.2018.1453496","article-title":"Cardiovascular Effects of Antimuscarinic Agents and Beta3-Adrenergic Receptor Agonist for the Treatment of Overactive Bladder","volume":"17","author":"Rosa","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/nau.20786","article-title":"Efficacy and Adverse Events of Sacral Nerve Stimulation for Overactive Bladder: A Systematic Review","volume":"29","author":"Siddiqui","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"B32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction","volume":"56","author":"St\u00f6hrer","year":"2009","journal-title":"Eur. Urol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sc.2016.168","article-title":"Effect of Imidafenacin on the Urodynamic Parameters of Patients with Indwelling Bladder Catheters Due to Spinal Cord Injury","volume":"55","author":"Sugiyama","year":"2017","journal-title":"Spinal Cord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.phrs.2009.01.002","article-title":"The Beta3-Adrenoceptor as a Therapeutic Target: Current Perspectives","volume":"59","author":"Ursino","year":"2009","journal-title":"Pharmacol. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with Prescribed Antimuscarinic Therapy for Overactive Bladder: A UK Experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/nau.23774","article-title":"A Pilot Randomized-Controlled Trial of the Urodynamic Efficacy of Mirabegron for Patients with Neurogenic Lower Urinary Tract Dysfunction","volume":"37","author":"Welk","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"B37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sc.2015.195","article-title":"Initial Experience with the Treatment of Neurogenic Detrusor Overactivity with a New \u03b2-3 Agonist (Mirabegron) in Patients with Spinal Cord Injury","volume":"54","author":"W\u00f6llner","year":"2016","journal-title":"Spinal Cord"},{"key":"B38","first-page":"9107","article-title":"Effective Treatment of Neurogenic Detrusor Overactivity in Multiple Sclerosis Patients Using Desmopressin and Mirabegron","volume":"24","author":"Zachariou","year":"2017","journal-title":"Can. J. Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.756582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T06:16:35Z","timestamp":1637216195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.756582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":38,"alternative-id":["10.3389\/fphar.2021.756582"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.756582","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"756582"}}